Switch to:
Also traded in: Germany, India, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.13
RDY's Cash to Debt is ranked lower than
62% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. RDY: 1.13 )
Ranked among companies with meaningful Cash to Debt only.
RDY' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.73 Max: No Debt
Current: 1.13
Equity to Asset 0.62
RDY's Equity to Asset is ranked higher than
50% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. RDY: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
RDY' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.56 Max: 0.82
Current: 0.62
0.31
0.82
Interest Coverage 31.95
RDY's Interest Coverage is ranked higher than
52% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. RDY: 31.95 )
Ranked among companies with meaningful Interest Coverage only.
RDY' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 17.11 Max: 34.89
Current: 31.95
3.11
34.89
F-Score: 6
Z-Score: 6.24
M-Score: -2.68
WACC vs ROIC
3.44%
20.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 19.68
RDY's Operating margin (%) is ranked higher than
81% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. RDY: 19.68 )
Ranked among companies with meaningful Operating margin (%) only.
RDY' s Operating margin (%) Range Over the Past 10 Years
Min: -4.08  Med: 17.08 Max: 19.7
Current: 19.68
-4.08
19.7
Net-margin (%) 15.69
RDY's Net-margin (%) is ranked higher than
80% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. RDY: 15.69 )
Ranked among companies with meaningful Net-margin (%) only.
RDY' s Net-margin (%) Range Over the Past 10 Years
Min: -7.44  Med: 14.38 Max: 16.28
Current: 15.69
-7.44
16.28
ROE (%) 20.89
RDY's ROE (%) is ranked higher than
84% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. RDY: 20.89 )
Ranked among companies with meaningful ROE (%) only.
RDY' s ROE (%) Range Over the Past 10 Years
Min: -11.56  Med: 23.40 Max: 29.21
Current: 20.89
-11.56
29.21
ROA (%) 12.34
RDY's ROA (%) is ranked higher than
83% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. RDY: 12.34 )
Ranked among companies with meaningful ROA (%) only.
RDY' s ROA (%) Range Over the Past 10 Years
Min: -6.1  Med: 12.11 Max: 13.76
Current: 12.34
-6.1
13.76
ROC (Joel Greenblatt) (%) 33.43
RDY's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. RDY: 33.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RDY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7.46  Med: 31.82 Max: 65.25
Current: 33.43
-7.46
65.25
Revenue Growth (3Y)(%) 15.10
RDY's Revenue Growth (3Y)(%) is ranked higher than
78% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. RDY: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RDY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.4  Med: 15.05 Max: 46.1
Current: 15.1
0.4
46.1
EBITDA Growth (3Y)(%) 14.50
RDY's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. RDY: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RDY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37  Med: 15.35 Max: 154.4
Current: 14.5
-37
154.4
EPS Growth (3Y)(%) 15.70
RDY's EPS Growth (3Y)(%) is ranked higher than
64% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. RDY: 15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RDY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65  Med: 32.55 Max: 154.7
Current: 15.7
-65
154.7
» RDY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

RDY Guru Trades in Q2 2015

Jim Simons 164,100 sh (+4002.50%)
Sarah Ketterer 544,600 sh (+1.78%)
Ken Fisher 5,198,254 sh (-0.34%)
» More
Q3 2015

RDY Guru Trades in Q3 2015

Jeremy Grantham 5,300 sh (New)
Sarah Ketterer 586,600 sh (+7.71%)
Ken Fisher 4,961,550 sh (-4.55%)
Jim Simons 117,200 sh (-28.58%)
» More
Q4 2015

RDY Guru Trades in Q4 2015

Jeremy Grantham 7,700 sh (+45.28%)
Ken Fisher 4,504,956 sh (-9.20%)
Sarah Ketterer 374,100 sh (-36.23%)
Jim Simons 70,700 sh (-39.68%)
» More
Q1 2016

RDY Guru Trades in Q1 2016

Ken Fisher 4,775,345 sh (+6.00%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.30
RDY's P/E(ttm) is ranked higher than
63% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. RDY: 21.30 )
Ranked among companies with meaningful P/E(ttm) only.
RDY' s P/E(ttm) Range Over the Past 10 Years
Min: 10.6  Med: 22.98 Max: 379.19
Current: 21.3
10.6
379.19
PE(NRI) 21.30
RDY's PE(NRI) is ranked higher than
63% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. RDY: 21.30 )
Ranked among companies with meaningful PE(NRI) only.
RDY' s PE(NRI) Range Over the Past 10 Years
Min: 10.59  Med: 22.99 Max: 380.55
Current: 21.3
10.59
380.55
Price/Owner Earnings (ttm) 17.23
RDY's Price/Owner Earnings (ttm) is ranked higher than
76% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. RDY: 17.23 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RDY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.42  Med: 58.07 Max: 612.23
Current: 17.23
11.42
612.23
P/B 4.03
RDY's P/B is ranked lower than
67% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. RDY: 4.03 )
Ranked among companies with meaningful P/B only.
RDY' s P/B Range Over the Past 10 Years
Min: 1.27  Med: 4.68 Max: 6.72
Current: 4.03
1.27
6.72
P/S 2.78
RDY's P/S is ranked lower than
51% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. RDY: 2.78 )
Ranked among companies with meaningful P/S only.
RDY' s P/S Range Over the Past 10 Years
Min: 0.94  Med: 3.02 Max: 5.29
Current: 2.78
0.94
5.29
PFCF 15.19
RDY's PFCF is ranked higher than
70% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. RDY: 15.19 )
Ranked among companies with meaningful PFCF only.
RDY' s PFCF Range Over the Past 10 Years
Min: 9.68  Med: 39.57 Max: 294.15
Current: 15.19
9.68
294.15
POCF 10.16
RDY's POCF is ranked higher than
76% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. RDY: 10.16 )
Ranked among companies with meaningful POCF only.
RDY' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 21.38 Max: 166.18
Current: 10.16
6.67
166.18
EV-to-EBIT 16.32
RDY's EV-to-EBIT is ranked higher than
60% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. RDY: 16.32 )
Ranked among companies with meaningful EV-to-EBIT only.
RDY' s EV-to-EBIT Range Over the Past 10 Years
Min: -495.9  Med: 17.40 Max: 276.7
Current: 16.32
-495.9
276.7
EV-to-EBITDA 12.54
RDY's EV-to-EBITDA is ranked higher than
65% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. RDY: 12.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.5  Med: 14.20 Max: 75.1
Current: 12.54
-43.5
75.1
PEG 0.59
RDY's PEG is ranked higher than
87% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. RDY: 0.59 )
Ranked among companies with meaningful PEG only.
RDY' s PEG Range Over the Past 10 Years
Min: 0.3  Med: 0.79 Max: 3.6
Current: 0.59
0.3
3.6
Shiller P/E 44.40
RDY's Shiller P/E is ranked higher than
50% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. RDY: 44.40 )
Ranked among companies with meaningful Shiller P/E only.
RDY' s Shiller P/E Range Over the Past 10 Years
Min: 41.49  Med: 59.53 Max: 69.17
Current: 44.4
41.49
69.17
Current Ratio 1.89
RDY's Current Ratio is ranked lower than
62% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. RDY: 1.89 )
Ranked among companies with meaningful Current Ratio only.
RDY' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.87 Max: 5.29
Current: 1.89
1.04
5.29
Quick Ratio 1.46
RDY's Quick Ratio is ranked lower than
60% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. RDY: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
RDY' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.38 Max: 4.3
Current: 1.46
0.68
4.3
Days Inventory 154.38
RDY's Days Inventory is ranked lower than
69% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. RDY: 154.38 )
Ranked among companies with meaningful Days Inventory only.
RDY' s Days Inventory Range Over the Past 10 Years
Min: 77.02  Med: 143.49 Max: 156
Current: 154.38
77.02
156
Days Sales Outstanding 101.51
RDY's Days Sales Outstanding is ranked lower than
68% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. RDY: 101.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.16  Med: 81.39 Max: 124.17
Current: 101.51
42.16
124.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.70
RDY's Dividend Yield is ranked lower than
75% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. RDY: 0.70 )
Ranked among companies with meaningful Dividend Yield only.
RDY' s Dividend Yield Range Over the Past 10 Years
Min: 0.3  Med: 0.62 Max: 1.4
Current: 0.7
0.3
1.4
Dividend Payout 0.14
RDY's Dividend Payout is ranked higher than
83% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. RDY: 0.14 )
Ranked among companies with meaningful Dividend Payout only.
RDY' s Dividend Payout Range Over the Past 10 Years
Min: 0.2  Med: 0.45 Max: 1.1
Current: 0.14
0.2
1.1
Dividend Growth (3y) 17.00
RDY's Dividend Growth (3y) is ranked higher than
71% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. RDY: 17.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RDY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -10.6  Med: 21.50 Max: 171.4
Current: 17
-10.6
171.4
Forward Dividend Yield 0.69
RDY's Forward Dividend Yield is ranked lower than
77% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. RDY: 0.69 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.73
RDY's Yield on cost (5-Year) is ranked lower than
54% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. RDY: 1.73 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RDY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.74  Med: 1.54 Max: 3.47
Current: 1.73
0.74
3.47
3-Year Average Share Buyback Ratio -0.10
RDY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.30 vs. RDY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -0.35 Max: -0.1
Current: -0.1
-6.6
-0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 12.94
RDY's Price/Net Current Asset Value is ranked lower than
75% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. RDY: 12.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RDY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.53  Med: 14.28 Max: 230.86
Current: 12.94
5.53
230.86
Price/Tangible Book 5.00
RDY's Price/Tangible Book is ranked lower than
66% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. RDY: 5.00 )
Ranked among companies with meaningful Price/Tangible Book only.
RDY' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.07  Med: 6.26 Max: 83.42
Current: 5
3.07
83.42
Price/Projected FCF 2.32
RDY's Price/Projected FCF is ranked higher than
55% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. RDY: 2.32 )
Ranked among companies with meaningful Price/Projected FCF only.
RDY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.47  Med: 3.06 Max: 4.6
Current: 2.32
1.47
4.6
Price/DCF (Earnings Based) 1.99
RDY's Price/DCF (Earnings Based) is ranked lower than
72% of the 71 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. RDY: 1.99 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.92
RDY's Price/Median PS Value is ranked higher than
69% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. RDY: 0.92 )
Ranked among companies with meaningful Price/Median PS Value only.
RDY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.02 Max: 1.85
Current: 0.92
0.39
1.85
Price/Peter Lynch Fair Value 0.85
RDY's Price/Peter Lynch Fair Value is ranked higher than
81% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. RDY: 0.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RDY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.06 Max: 1.97
Current: 0.85
0.54
1.97
Price/Graham Number 2.18
RDY's Price/Graham Number is ranked lower than
52% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. RDY: 2.18 )
Ranked among companies with meaningful Price/Graham Number only.
RDY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.66  Med: 2.63 Max: 11.33
Current: 2.18
1.66
11.33
Earnings Yield (Greenblatt) (%) 6.08
RDY's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. RDY: 6.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RDY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 5.30 Max: 11.6
Current: 6.08
0.4
11.6
Forward Rate of Return (Yacktman) (%) 29.13
RDY's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. RDY: 29.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RDY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -9.4  Med: 1.70 Max: 48.4
Current: 29.13
-9.4
48.4

More Statistics

Revenue(Mil) $2338
EPS $ 2.14
Beta0.68
Short Percentage of Float3.11%
52-Week Range $40.68 - 68.00
Shares Outstanding(Mil)170.61

Analyst Estimate

Mar16 Mar17
Revenue(Mil) 2,479 2,610
EPS($) 2.20 2.05
EPS without NRI($) 2.20 2.05

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:RDDA.Germany, 500124.India, RDY N.Mexico,
Dr Reddy Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-based pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ("APIs"), Custom Pharmaceutical Services ("CPS"), generics, biosimilars, differentiated formulations and New Chemical Entities ("NCEs"). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company's biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company's differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company's specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company's competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company's manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and guide
» More Articles for RDY

Headlines

Articles On GuruFocus.com
Ken Fisher Sells Shares of PMC Sierra, Alphabet During 4th Quarter Jan 15 2016 
Emerging Market Stocks To Watch Out For Feb 17 2015 
Should You Buy Actavis? Mar 18 2014 
Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 

More From Other Websites
Earnings Call Notification Apr 26 2016
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May... Apr 26 2016
Management Council Apr 25 2016
ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
How Have India’s Industry and Services Sectors Performed? Apr 19 2016
China Takes a Breather as India Drives Growth in Asia Apr 07 2016
Investing in Indian Stocks: Active versus Passive Modes Apr 05 2016
Not a Good 1Q16 for Indian Stocks, but Is the Tide Turning? Apr 05 2016
Cutispharma, Dr. Reddy's Laboratories Announce Partnership Apr 05 2016
Dr. Reddy's Acquires Anticancer Drug Rights from Eisai Apr 01 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S,... Mar 31 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain... Mar 31 2016
Dr Reddy's Collaborates with XenoPort for Psoriasis Drug Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s and TR-Pharm Announce Strategic Collaboration in Turkey Mar 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK